Immunoreactivity of the 14F7 Mab raised against <i>N</i>‐Glycolyl <scp>GM</scp>3 Ganglioside in retinoblastoma tumours

Torbidoni, V.; Scursoni, Alejandra M.; Camarero, Sandra; Segatori, Valeria Inés; Gabri, Mariano Rolando; Alonso, Daniel F.; Chantada, Guillermo; Davila, María Teresa de

doi:10.1111/aos.12578

Cited by 26 publications

(23 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New biomarkers for molecular dissemination of retinoblastoma outside the eye may lead to earlier diagnosis of metastasis and targeted treatments. 92,93 …”

Section: Discussionmentioning

confidence: 99%

“…82,84 However, still too frequently retrospective examination finds a previously unnoticed risk after metastatic disease is diagnosed. Staining of specific markers for photoreceptor cells (the cone-rod homeobox transcription factor; CRX) 92 and for tumour cells (N-glycosylated ganglioside; NeuGc-GM3) 93 may facilitate detection of tumour cells otherwise missed or interpreted as artefact.…”

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%

See 1 more Smart Citation

Retinoblastoma

Dimaras

Corson

Cobrinik

et al. 2015

Nat Rev Dis Primers

424

390

View full text Add to dashboard Cite

Retinoblastoma is a rare cancer of the infant retina, which forms when both RB1 alleles mutate in a susceptible retinal cell, likely a cone photoreceptor precursor. Loss of the tumour suppressor functions of the retinoblastoma protein, pRB, leads to uncontrolled cell division and recurrent genomic changes during tumour progression. Although pRB is expressed in virtually all tissues, cone precursors have biochemical and molecular features that may sensitize to RB1 loss to enable tumourigenesis. Retinoblastoma is diagnosed in ~8,000 children each year worldwide. Patient survival is >95% in high-income countries, but <30% globally. However, outcomes are improving through increasing awareness for earlier diagnosis, new guidelines and sharing of expertise. Intra-arterial and intravitreal chemotherapy have emerged as promising methods to salvage eyes. Ongoing international collaborations will replace the multiple different classifications of eye involvement with standardized definitions to consistently assess eligibility, efficacy and safety of treatment options. Life-long follow-up is warranted since survivors of heritable retinoblastoma are at risk for developing second cancers. Defining the molecular consequences of RB1 loss in diverse tissues may open new avenues for treatment and prevention of retinoblastoma as well as second cancers in patients with germline RB1 mutations.

show abstract

“…New biomarkers for molecular dissemination of retinoblastoma outside the eye may lead to earlier diagnosis of metastasis and targeted treatments. 92,93 …”

Section: Discussionmentioning

confidence: 99%

Section: Diagnosis Screening and Preventionmentioning

confidence: 99%

Retinoblastoma

Dimaras

Corson

Cobrinik

et al. 2015

Nat Rev Dis Primers

424

390

View full text Add to dashboard Cite

show abstract

“…This immunotherapy was designed to induce an immune response against the N-glycolil GM3 ganglioside and it was already tested in phase I study in patients with neuroblastoma 20. We have previously demonstrated that Rb cells showed important amount of this ganglioside 24. Immunotherapy is under consideration for other brain tumours, so we could not rule out the possibility of a contribution of the immune system in limiting intracranial tumour progression in this case 25…”

Section: Discussionmentioning

confidence: 99%

Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Patients in whom CRX was detected in the BM and/or CSF or GD2 synthase was detected in the CSF were considered as having MDD. The CRX mRNA positivity was expressed as relative expression levels according to our previous work . GD2 synthase results were shown as qualitative data (positive‐negative) .…”

Section: Methodsmentioning

confidence: 99%

“…Bone marrow (BM) and CSF were collected as part of a prospectively defined schedule-at diagnosis, following induction chemotherapy, and in relapsed cases when disease was suspected clinically or by imaging studies. [10][11][12] For MDD determination in the CSF, we used the detection of the mRNA of GD2 synthase as it was already reported 9 until it was replaced by CRX mRNA detection. 10 Specimens for MDD were blindly processed by the polymerase chain reaction operators.…”

Section: Mdd Evaluationmentioning

confidence: 99%

Minimally disseminated disease and outcome in overt orbital retinoblastoma

Aschero

Torbidoni

Sampor

et al. 2019

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

In this retrospective study of patients with overt orbital retinoblastoma, we evaluated minimally disseminated disease (MDD) in bone marrow and cerebrospinal fluid (CSF) using CRX and/or GD2 synthase as markers. Ten patients were evaluated—five (50%) at diagnosis and five upon relapse. MDD was detected in four cases (one in the bone marrow, two in the CSF, and in one case in both sites). All patients received chemotherapy and four received orbital radiotherapy. Seven patients relapsed or progressed and all of them died. Three patients remain in complete remission. There was no apparent correlation between MDD and the outcome.

show abstract

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Cited by 26 publications

References 47 publications

Retinoblastoma

Retinoblastoma

Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma

Minimally disseminated disease and outcome in overt orbital retinoblastoma

Contact Info

Product

Resources

About